» Articles » PMID: 33484167

Pre- and Postoperative Ga-DOTATOC Positron Emission Tomography for Hormone-secreting Pituitary Neuroendocrine Tumours

Overview
Specialty Endocrinology
Date 2021 Jan 23
PMID 33484167
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Somatostatin receptors (SSTRs) are potential targets for detecting pituitary neuroendocrine tumours (PitNETs) that can be visualized effectively with Ga-labelled PET tracers. With this study, we have evaluated the diagnostic properties of such a tracer, Ga-DOTATOC, in patients with hormone-producing PitNETs before and after surgery.

Design/methods: This prospective case-control study presents preoperative positron emission tomography (PET) and histopathological data in 18 patients with somatotroph (n = 8), corticotroph (n = 7) and thyrotroph (n = 3) PitNETs. Patients were scanned pre- and postoperatively with Ga-DOTATOC PET. For the postoperative part of the study, patients with gonadotroph tumours (n = 7) were also included. Fifteen pituitary healthy controls underwent the same protocol once. The maximum standard uptake value (SUV ) was analysed in manually outlined regions around the tumour in patients and around the pituitary gland in controls. specimens were collected during surgery in subjects for assessment of adenohypophyseal tumour cell type and the SSTR expression.

Results: Thyrotroph tumours showed higher uptake (median SUV 41.1; IQR 37.4-60.0) and corticotroph tumours lower uptake (SUV 6.8; 2.6-9.3) than normal pituitary gland (SUV 13.8; 12.1-15.5). The uptake in somatotroph tumours (SUV 15.9; 11.6-19.7) was similar to the uptake in the pituitary gland. There was a strong correlation between SUV and SSTR2 expression (r = .75 (P < .01)). In the postoperative evaluation, PET was able to correlate tracer uptake with biochemical cure and noncure in patients with an abnormal postoperative magnetic resonance image and a preoperative tumour uptake SUV  > 13.8.

Conclusions: Ga-DOTATOC PET can be used to detect thyrotroph tumours in the pre- and postoperative imaging assessment. Corticotroph tumours had a significantly lower uptake compared to the pituitary gland but without a distinct increased tumour uptake the clinical postoperative value is limited.

Citing Articles

EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.

Van Weehaeghe D, Lapauw B, Fraioli F, Cecchin D, Verger A, Guedj E Eur J Nucl Med Mol Imaging. 2024; 51(8):2367-2370.

PMID: 38687371 DOI: 10.1007/s00259-024-06728-4.


Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.

Iglesias P J Clin Med. 2024; 13(1).

PMID: 38202123 PMC: 10779494. DOI: 10.3390/jcm13010116.


The utility of PET for detecting corticotropinomas in Cushing disease: a scoping review.

Bauman M, Graves J, Harrison D, Hassett L, Bancos I, Johnson D Neurosurg Rev. 2023; 46(1):160.

PMID: 37393399 DOI: 10.1007/s10143-023-02077-2.


Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors.

Bianchi A, Chiloiro S, Giampietro A, Gaudino S, Calandrelli R, Mazzarella C Front Endocrinol (Lausanne). 2023; 14:1123267.

PMID: 37206441 PMC: 10189777. DOI: 10.3389/fendo.2023.1123267.


Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction.

Gillett D, Senanayake R, MacFarlane J, van der Meulen M, Koulouri O, Powlson A EJNMMI Res. 2022; 12(1):26.

PMID: 35524902 PMC: 9079199. DOI: 10.1186/s13550-022-00899-7.